Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 through 75 years at the time of screening~* Adequate contraception from screening through end of trial~* Weight of more than (\>) 45 kilogram (kg) but less than or equal to (\<=) 150 kg (\>100 pound \[lb\] but \<=330 lb)~* History of physician-diagnosed asthma for at least 12 months prior to screening~* Physician prescribed daily use of medium-dose or high-dose inhaled corticosteroid(s) (ICS) plus long-acting beta 2 agonist (LABA) for at least 12 months prior to screening~* Willingness to switch to an ICS/LABA combination product~* Dose of other asthma controller medications must be stable for at least 30 days prior to screening~* At least 2 documented asthma exacerbations in the 12 months prior to screening that required use of a systemic corticosteroid burst~* For subjects 65 years of age or older, a chest x-ray (CXR) or chest computed tomography (CT) that is normal for an asthmatic population~* Ability and willingness to complete the study to Week 66, and if needed to Week 92.~Exclusion Criteria:~* Known history of allergy or reaction to any component of the investigational product formulation~* History of anaphylaxis to any biologic therapy~* Unexplained diarrhea within 30 days prior to screening or diagnosis of helminth parasitic infestation within 6 months prior to screening~* Use of immunosuppressive medication within 3 months prior to screening. Chronic oral prednisone or equivalent up to 10 milligram (mg) daily or 20 mg every other day for asthma is allowed~* Oral corticosteroid burst or short-acting systemic corticosteroid within 30 days prior to screening or during the screening/run-in period~* Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 30 days prior to the screening or during the screening/run-in period~* Receipt of immunoglobulin or blood products within 30 days prior to screening~* Receipt of any marketed or investigational biologic within 4 months or 5 half-lives prior to screening, whichever is longer~* Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to screening, whichever is longer~* Previously received MEDI-563~* Any clinically relevant abnormal findings in physical examination~* Past history of clinically significant cardiac disease or any electrocardiogram (ECG) abnormality~* Breastfeeding or lactating women~* History of alcohol or drug abuse within 12 months prior to screening~* History of any known primary immunodeficiency disorder~* Positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enrol~* A positive human immunodeficiency virus (HIV) test or subject taking antiretroviral medications~* History of cigarette smoking more than or equal to (\>=) 10 pack-years or smoking within 12 months prior to screening.~* Known exposure to inhaled occupational agents or fumes with an established diagnosis of occupational asthma~* History of cancer, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy \>=12 months prior to screening or other malignancies treated with apparent success with curative therapy \>=5 years prior to screening~* Stable dose of allergy vaccination regimen for less than 30 days prior to screening~* Subjects unable to demonstrate acceptable inhaler and peak flow meter techniques.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Eosinophilic phenotype (EOS+) Placebo (Type: PLACEBO_COMPARATOR): EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
- EOS+ Benralizumab (2 mg) (Type: EXPERIMENTAL): EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
- EOS+ Benralizumab (20 mg) (Type: EXPERIMENTAL): EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
- EOS+ Benralizumab (100 mg) (Type: EXPERIMENTAL): EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
- Non-eosinophil phenotype (EOS-) Placebo (Type: PLACEBO_COMPARATOR): EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
- EOS- Benralizumab (100 mg) (Type: EXPERIMENTAL): EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

Based on this trial design, predict the completion outcome and termination type (if applicable).